1. Home
  2. FMY vs SCYX Comparison

FMY vs SCYX Comparison

Compare FMY & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FMY
  • SCYX
  • Stock Information
  • Founded
  • FMY 2005
  • SCYX 1999
  • Country
  • FMY United States
  • SCYX United States
  • Employees
  • FMY N/A
  • SCYX N/A
  • Industry
  • FMY Finance/Investors Services
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FMY Finance
  • SCYX Health Care
  • Exchange
  • FMY Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • FMY 51.1M
  • SCYX 40.9M
  • IPO Year
  • FMY N/A
  • SCYX 2014
  • Fundamental
  • Price
  • FMY $12.19
  • SCYX $0.95
  • Analyst Decision
  • FMY
  • SCYX Buy
  • Analyst Count
  • FMY 0
  • SCYX 1
  • Target Price
  • FMY N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • FMY 10.1K
  • SCYX 115.0K
  • Earning Date
  • FMY 01-01-0001
  • SCYX 03-12-2025
  • Dividend Yield
  • FMY 6.98%
  • SCYX N/A
  • EPS Growth
  • FMY N/A
  • SCYX N/A
  • EPS
  • FMY N/A
  • SCYX N/A
  • Revenue
  • FMY N/A
  • SCYX $3,746,000.00
  • Revenue This Year
  • FMY N/A
  • SCYX $1,541.00
  • Revenue Next Year
  • FMY N/A
  • SCYX $111.43
  • P/E Ratio
  • FMY N/A
  • SCYX N/A
  • Revenue Growth
  • FMY N/A
  • SCYX N/A
  • 52 Week Low
  • FMY $10.71
  • SCYX $0.82
  • 52 Week High
  • FMY $12.17
  • SCYX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • FMY 55.97
  • SCYX 42.75
  • Support Level
  • FMY $12.12
  • SCYX $0.94
  • Resistance Level
  • FMY $12.22
  • SCYX $1.06
  • Average True Range (ATR)
  • FMY 0.07
  • SCYX 0.06
  • MACD
  • FMY 0.01
  • SCYX -0.00
  • Stochastic Oscillator
  • FMY 87.05
  • SCYX 38.46

About FMY First Trust Motgage Income Fund of Beneficial Interest

First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: